IRCT20100119003106N46招募中Unknown
It Is a Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Assessment of the Effects of Postbiotic Supplementation with Lactobacillus rhamnosus CRL 1505 and Lactobacillus acidophilus (Johnsonii) La1, with a Focus on Interferon-Beta and Interleukin 6 ; Impact on Upper Respiratory Tract Infection Incidence
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •Adult men and women aged between 18 and 65 years who have a thorough comprehension of the potential risks and benefits.
- •They are required to sign informed consent forms before participating.
排除标准
- •Unwillingness to continue or participate in the study
- •Diagnosis of immunodeficiency due to any diagnosed chronic disease
- •Gastrointestinal ulcer
- •Liver and kidney dysfunction
- •Human immunodeficiency virus
- •Autoimmune disorders
- •Malignancy or any history of malignancy
- •Any diagnosis of respiratory diseases with cold or flulike symptoms
- •Severe diseases such as asthma and severe allergies
- •Pregnancy, breastfeeding
- •Drug or alcohol addiction
- •Taking any immunosuppressants or immunomodulators
研究者
相似试验
已完成
1 期
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety and Pharmacokinetics of CHI-541 among Healthy ParticipantsPainNauseaMuscle SpasticityAlternative and Complementary Medicine - Other alternative and complementary medicineEpilepsyACTRN1261900172317810607410 CANADA INC. DBA Spectrum Therapeutics41
已完成
1 期
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety and Pharmacokinetics of CHI-936 in Healthy ParticipantsPainNauseaMuscle SpasticityAlternative and Complementary Medicine - Other alternative and complementary medicineEpilepsyACTRN1261900145010110607410 CANADA INC. DBA Spectrum Therapeutics43
已完成
不适用
A study on the pain reducing effect of terminalia chebula.CTRI/2014/10/005106IZAMS INSTITUTE OF MEDICAL SCIENCES24
进行中（未招募）
不适用
A clinical trial in subjects who suffer from hay fever to see the effects of the study medication, SB-705498, when taken on its own or in conjunction with a background therapy, Fluticasone Propionate, on the symptoms triggered by an allergen challenge chamber session.EUCTR2011-000115-11-ATGlaxoSmithKline Research and Development Ltd72
进行中（未招募）
1 期
An efficacy and safety study of 2-OHOA in patients with glioblastomaewly diagnosed primary glioblastoma multiforme (ndGBM)MedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864CTIS2024-511542-39-00aminar Pharmaceuticals S.A.140